



Date: 30.06.2026

To
BSE Limited
Phiroze Jeejeebhoy Towers, Dalal Street
Mumbai – 400001

Dear Sir/Madam,

Scrip Code: 524572 | Scrip ID: PHARMAID | ISIN: INE117D01018

Sub: Appointment of Internal Auditor - Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”)

Pursuant Regulation 30 read with Schedule III of Listing Regulations, the Board of Directors of the Company at their meeting held today i.e. on Tuesday, June 30, 2026, have, inter alia, basis recommendation of the Audit Committee, considered and approved the appointment of M/s. V Mahendra & Associates Chartered Accountants (FRN: 025356S) as Internal Auditors of the Company for carrying out the Internal Audit for the financial year 2026-27.

The disclosure as required under Regulation 30 of the Listing Regulations read with SEBI Master Circular dated January 30, 2026, is enclosed as **Annexure A**.

The above Information is being made available on the Company’s website i.e, www.pharmaids.com

Kindly take the same on your record and oblige.

For Pharmaids Pharmaceuticals Limited

Prasanna Subramanya Bhat
(Company Secretary & Compliance Officer)



Disclosure as per SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

Sl. No.	Particulars	Details
1	Reason for change viz. appointment, resignation, removal, death or otherwise	Appointment of M/s. V Mahendra & Associates Chartered Accountants (FRN: 025356S), as the Internal Auditors of the Company for carrying out the Internal Audit for the financial year 2026-27.
2	Date of appointment / cessation	The Board at its meeting held today, i.e. on 30 June 2026, approved the appointment of M/s. V Mahendra & Associates, as Internal Auditors of the Company.
3	Brief Profile	<p>M/s. V Mahendra & Associates is a Chartered Accountant firm, having professional experience of more than 23 years.</p> <p>The firm has been actively associated with corporate entities in ensuring compliance with statutory requirements, strengthening internal controls, improving financial reporting systems, and enhancing operational efficiency.</p>
4	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable